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State of the Art
Transforming Research
Methodologies in EU Life
Sciences and Biomedicine
Gender-Sensitive Ways of Doing
Research
Ineke Klinge and Mineke Bosch
MAASTRICHT UNIVERSITY
ABSTRACT This article describes how methodologies of EU-funded research
within the life sciences and biomedicine have recently become more gender sensi-
tive. This transformation is the result of the Gender Impact Assessments of the EU
Fifth Framework Programme, commissioned in 2000–1. The authors assessed the
research programme for life sciences, which includes a large health-related
component. The new guidelines for research emphasize the need for clear termi-
nology for concepts of sex and gender and for a distinction to be made between
the two, for both life sciences and health research. Attention to possible sex differ-
ences, even in preclinical research, as well as to effects of gender, will lead to more
adequate research data that serve the health of both men and women. The trans-
formation to research becoming more gender-sensitive is further discussed in the
context of feminist theory on the body. Being fully aware of the fact that what is
happening in bodies is mediated by particular technologies, the authors make an
appeal to invest in concepts that take the living and changing body into account.
KEY WORDS gender differences ◆ gender-sensitive policies ◆ health-related
research ◆ mainstreaming gender (equality) ◆ quality of research ◆ sex
differences
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INTRODUCTION
Feminist involvement with life sciences and biomedical research has a
long-standing tradition. Beginning with early publications such as Alice
through the Microscope by the Brighton Women and Science Group (1980),
which focuses on science and women’s lives, gender studies in life
sciences and biomedicine developed into a vast research area by the onset
of the 21st century. Handbooks and comprehensive reviews have
appeared and many researchers are actively involved in tackling today’s
problems as regards gender and health.1 Specialized journals have been
launched such as Women and Health and Journal of Women’s Health and
Gender-Based Medicine, later abbreviated to Journal of Women’s Health. In
Europe, four international congresses on gender and health were organ-
ized by the European Association of Women and Health Research
(EAWHR), in Amsterdam (1997), Edinburgh (2000) and Vienna (2002).
The fourth congress recently took place in Tallin, 25–27 April 2005.
The early rationale for feminist involvement with biomedical research
in the 1970s was, to put it simply, primarily due to the way women were
treated by the medical establishment. Patriarchal attitudes, neglectful of
women’s concerns with the ‘male’ norm in research and treatment, were
convincingly exposed. Even more systematically, the core critique was
subsequently summarized in terms of medicalization, psychologization
and the trivialization of women’s symptoms (Bekker et al., 1999). At the
onset, one of the assignments of gender studies was a critique of science.
Feminist scholars attacked the epistemological premises of biomedical
research: they questioned the positivist framework of discovering
unpalatable truths about health and disease. Many of them called for a
constructivist approach to biomedicine. This branch of research has
yielded a wealth of interesting case studies, for example on the construc-
tion of the premenstrual syndrome or the menopause, thereby acknowl-
edging the processes of gender. However, these new insights did not seem
to have an impact on everyday research practices in the life sciences and
biomedicine.
The first change in research practices that took place was not an
epistemological one but rather a methodological one. In the USA, a
redressing of standard practice occurred in the sense that the exclusion of
women as objects of research was corrected. The Office of Research on
Women’s Health of the US National Institute of Health (NIH) has, thus,
been successful in bringing about a fundamental change in a particular
research practice, e.g. that of the clinical trial. However, it required the
joint effort of academic feminists, congressional leaders, medical doctors
at NIH and the women’s movement (Schiebinger, 1999) to accomplish this
change. New drugs were usually tested on a population of healthy young
men between 20 and 40. Once the drug under study was eventually
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approved by the Food and Drug Administration (FDA), it then could be
prescribed for all, including women, the elderly, children and ethnic
minorities. The (white) male norm in research, based on the argument that
the menstrual cycle in women would disturb the testing, came under
attack.2 Evidence was put forward that showed that ‘traditional’ test
results could not be extrapolated. The drugs thus developed did not
promote women’s health because either no effects or different, sometimes
harmful effects were reported. As a result of the coordinated efforts
described previously, all future clinical research carried out with grants
from the NIH has to adhere to guidelines stipulating the inclusion of
women and minorities in research (NIH, 1994, 2000). A well-known
example of this kind of reform of research practices concerns the diag-
nosis and treatment of coronary heart disease in women. Differences
between men and women now taken into account are condition-specific
aspects such as pathogenesis, pattern of symptoms and presentation of
symptoms, treatment options and prognosis.3
In this article, a feminist intervention in EU-funded research is central.
We describe how the gender mainstreaming of research policy resulted in
recommendations for a new research methodology. In 2000, the European
Commission asked for a Gender Impact Assessment (GIA) of their Fifth
Framework Programme for Research and Technological Development
(1998–2002) (FP5). Carrying out such a GIA offered a unique opportunity
for taking a significant step forward in translating feminist insights into
the life sciences and health research. We conducted the GIA of the FP5
research programme for the life sciences known as ‘Quality of Life and
Management of Living Resources’ (QoL). A large part of this programme
for life sciences research, which consisted of six key actions and seven
generic activities, comprises health-related research. Based on and backed
by a wealth of evidence from existing research, we set out to suggest a
transformation of the ‘traditional’ life sciences and health research
methodology into a gender-sensitive one. Gender-sensitive in this respect
has to be understood as renewed attention to sex differences (without
falling into essentialist traps), together with an awareness of possible
gender effects. We first give an outline of the policy framework of the GIA
studies; namely the policy of gender mainstreaming. Next, the GIA study
itself is the focal point of attention. We continue with the implementation
of our recommendations for gender-sensitive research in the Framework
Programme FP6 (2002–6) by giving examples from current EU research
projects and activities. In the final section, we discuss this transformation
in the context of feminist theory on the body.
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CONTEXT OF THE GIA STUDY: GENDER MAINSTREAMING
EU RESEARCH
An important moment in the worldwide adoption of gender mainstream-
ing was the United Nations Fourth World Conference on Women, held in
Beijing in 1995.4 A year earlier, the Council of Europe had already come
up with a definition, which remains influential: ‘Gender mainstreaming is
the (re)organisation, improvement, development and evaluation of policy
processes so that a gender equality perspective is incorporated in all
policies and at all stages by the actors normally involved in policy-
making’ (Council of Europe, 1998; Stevens and van Lamoen, 2001). In
1996, the European Commission issued the Communication Incorporating
Equal Opportunities for Women and Men into all Community Policies and
Activities (European Commission, 1996). In 1997, this commitment to the
gender mainstreaming of all EU policies became a ‘fundamental principle’
of Community Activity in the Treaty of Amsterdam. Since then, main-
streaming gender equality has become a topic in various community
policies and activities as well as in the member states; and interestingly,
also in EU science policies.
In 1998, Commissioner Edith Cresson seriously took up this assign-
ment, helped by the wave of indignation that shook the world of science
after the publication of the analysis by the Swedish researchers Wold and
Wennerås of the selection process of the Swedish Medical Research
Council (Wold and Wennerås, 1997). When launching FP5, the European
Commission decided to include an equal opportunities dimension by
promoting women’s participation in European research. In February 1999,
it adopted the Communication Women and Science: Mobilising Women to
Enrich European Research, in which it acknowledged the severe underrep-
resentation of women in science. Even more important was the fact that
the communication defined the policy task to promote gender equality in
terms of three dimensions that were put forward as characteristic of the
relation between gender and science: science by women, science for
women and science about women (European Commission, 1999). Here
the active lobbying of Women’s International Studies Europe (WISE) may
have had an impact.5 The 1999 Action Plan of the Women and Science
Unit within DG Research subsequently formulated two objectives: the
organization of a Policy Forum to feed the policy process and to develop
collective strategies and the creation of a Gender Watch System to
evaluate the EC’s goal to promote science by, for and about women (see
also European Commission, 2001a).
As part of the Policy Forum, a group of national experts (the so-called
ETAN group) was mandated to analyse the current position of female
scientists in the European academic world. In 2000, this group published
an extensive report, Science Policies in the European Union, Promoting
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Excellence through Mainstreaming Gender Equality, in which multiple
aspects of the relation between women, gender and science on the basis of
experiences from all member states were highlighted. Although the focus
was primarily on the underrepresentation of women in science, the
gender dimension of the content of science was certainly not absent.
Moreover, gender mainstreaming was identified as a vital precondition
for promoting excellence in EU science policy and her member states
(European Commission, 2000). Recently, a follow-up report was
published by the so-called ENWISE group, which covers the same subject
in the new member states (European Commission, 2004). Another point of
action taken as part of the Policy Forum was the establishment of the so-
called Helsinki Group, consisting of national civil servant representatives
from all countries associated with FP5. This group assists the European
Commission in collecting statistics and indicators that allow for a
comparison at European level and published the report National Policies on
Women and Science in Europe (European Commission, 2002b). These indi-
cators not only record women’s participation at all levels of science, but
also the presence of women’s and gender studies, or the absence or
presence of policies regarding the issue of women and science. Another
result of the Policy Forum was the publication of She Figures 2003, a collec-
tion of statistics on women in science on the basis of an interesting set of
indicators (European Commission, 2003).
The Gender Watch System, set up to monitor the impact of gender on
the European Commission’s Framework Programmes, consists of two
pillars. The first involves promoting women’s participation in FP5. To this
end, in 2000 the Commission set the target of 40 percent participation of
women at all levels of EU research policy. The second pillar concerns an
evaluation of the gender dimension in the development, management
and implementation of the Framework Programmes, beginning with FP5.
For this purpose, the EC commissioned a series of GIA studies of all
specific programmes within FP5. These studies, which were carried out by
seven groups of researchers, investigated the participation of women and
analysed whether the research themes, methods and issues prioritized in
FP5 affect women and men differently. The conclusions and recommen-
dations of the GIAs were meant to be fed back into the preparation and
implementation of the next Framework Programme (FP6).
This is not the place to discuss (or praise) the efficacy of the policy-
making process in DG Research that is the result of an interesting coalition
between groups that often act separately: (feminist) bureaucrats or equal
opportunities officers, gender studies scholars and women scientists.
However, we do wish to stress the window of opportunity that was
created by the definition of the ‘women and science question’ as science
or research by, for and about women. In our view, the focus on partici-
pation of women as well as on the content of research (recently expressed
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in the symbolic formula GE = GD + WP, i.e. Gender Equality = Gender
Dimension + Women’s Participation) in the Communication and in the
assignments for the GIA studies is groundbreaking and potentially
disruptive of the existing gender order of science.6
GIA OF THE RESEARCH PROGRAMME FOR THE LIFE
SCIENCES (QOL)
In the call for tender announcing the seven (originally eight) gender
impact studies, each covering a part of the Fifth Framework Programme,
the aims were not unequivocally defined. The gender dimension of the
Work Programme and the actual projects could be taken as objects of
analysis, as well as the evaluation process or the issue of women’s partici-
pation. We therefore decided to create some clarity in our application, by
focusing on the three aspects of gender and research mentioned in the
Communication: (1) to analyse research by women, or women’s partici-
pation at all levels of the programme and in the EU staff involved in the
QoL programme; (2) to analyse research for women, or the question
whether the Work Programme, the calls and the funded research were
addressing women’s needs; and (3) to analyse research about women, or
whether any research was invited (in the Work Programme) or under-
taken (in the actual funded projects) that focused on ‘women’, on the
relationship between men and women or on gender and health issues.
The applicants for tender were supposed to start with a state of the art
bibliography as a background for the assessment. Also, they were
required to develop their own methodology. At first we were rather aston-
ished by the lack of uniformity the Commission had established for the
execution of the GIAs. How could the various studies undertaken be
compared in the end, given the fact that a synthesis report was foreseen?
Looking back, however, we appreciate the freedom the Commission
allowed the research teams to develop their own research designs. They
certainly came up with a diversity of methodologies and approaches from
which the Commission can now benefit.
RESEARCH BY WOMEN OR WOMEN’S PARTICIPATION (WP)
The participation of women (research by women) at all levels was
assessed in quantitative terms. Depending on the kind of commission,
panel or projects, the figures were broken down according to member
states and/or candidate countries, key action or function (researcher or
coordinator for example). We also decided to analyse the participation of
women (A-grade) in QoL staff as part of the European science process.
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The participation of women in committees and panels that were
controlled or easily influenced by the Commission’s services came close to
the 40 percent rule, set as the main objective. In the different Expert
Advisory Groups (for the different key actions within the programme),
the average percentage of women participation was 37 percent, ranging
from 53 percent (key action ‘The “Cell Factory”’) to 11 percent (key action
‘Sustainable Agriculture, Fisheries and Forestry’). The ‘invisible hand’ of
the Commission became especially visible in the evaluation panels. Here,
the average participation of women in one of the calls was 25.7 percent,
which is almost 9 percent higher than the 17 percent women in the QoL
evaluators’ database.
The participation of women dropped, however, when the European
Commission had less influence on the appointment procedure or when it
did not fall under its control. Thus, among the delegate members to the
Programme Committees, women were represented by 24 percent. Nine
countries had no female delegate, as opposed to two countries without a
male representative. With respect to the participation of women in
projects, the prospects were even worse with a mere 18 percent women in
the project research teams that passed the selection for the first two calls
(first deadlines) of the QoL Programme. The participation of women in
QoL staff was also below the EC’s target of 40 percent, which, according
to one informant, was due to the ‘bachelor culture’ prevalent in European
services. We were not able to assess the representation of gender expertise
among the women (and some men) in the various committees, panels and
projects, but made a point of explaining that the representation of women
per se could not alter the development of research programmes or project
evaluation procedures. The actual participation of women is only one
aspect of the gender order of science. Therefore, one of the recommen-
dations addressed the need to make the participation of women an
integral part of the evaluation procedure; another was to include the
participation of gender experts in all the implementation committees and
panels.
RESEARCH FOR AND ABOUT WOMEN OR THE GENDER
DIMENSION (GD) OF RESEARCH
Right from the start, we assessed that what was missing in the tender text
was the concept of ‘sex’. Particularly in the life sciences, both sex and
gender are relevant and consequently we established a clear terminology.
We defined sex as a biological quality and gender as a sociocultural
process, both of equal importance in relation to health-related research.
We did so to counter prevailing and confusing notions, which assume that
gender is ‘a women’s issue’ (and not an issue that also affects men’s
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health) and that the concepts of sex and gender can be used interchange-
ably. The latter, for instance, was suggested by the ‘gender box’ on the
application forms.7 Although we are fully aware of ongoing debates
within feminist theory questioning the distinction between sex and
gender, for disciplines like biomedicine and health sciences this concep-
tual distinction is necessary. Differences between women and men
concerning individual health or sensitivity to drugs, or differences in
encounters with the health care system, can be attributed to both sex
differences and differences resulting from gender. The ‘integration of the
gender dimension’, the terminology used by the Commission at the time,
in relation to health-related research, should therefore encompass sex
differences and differences resulting from gender.
METHODOLOGY
To conduct our analysis of the gender dimension of the QoL Programme
and QoL projects, we used the Gender Impact Resource as bibliographic
background. This enabled us to analyse the Work Programme. The
Gender Impact Resource was compiled from searches in two databases of
which one, the IIAV, is specialized in literature addressing gender
research, whereas the second one, MEDLINE, is a mainstream biomedical
research database (IIAV, 1998). MEDLINE needed ‘special treatment’ to
retrieve what we understood by gender-sensitive research. The biblio-
graphic resource we compiled was rich in illustrating both sex and gender
differences and it facilitated the task to convince our partners in DG
Research of the relevance of sex and gender aspects in conducting health
research (Bird and Rieker, 1999; Fishman et al., 1999; Lorber, 2001;
Williams, 2000).
For the analysis of projects (research proposals that have passed the
evaluation process and are funded by the EU), we developed a Gender
Impact Assessment Protocol (GIA Protocol), inspired by existing instru-
ments for gender-based analysis but tailored to the EU research
procedures. The main steps or questions in the Protocol are the following:
(1) Is sex and/or gender relevant to the project (relevance check and litera-
ture check)? (2) Is sex and/or gender addressed by the project? (3) How
are sex and/or gender issues addressed (criteria)?8
RESULTS
The integration of the gender dimension in terms of the attention paid to
sex and gender differences in the Work Programme turned out to be fairly
limited. A clear articulation of gender aspects in relation to the thematic
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priorities of the programme was lacking. In the key action on ‘Food,
Nutrition and Health’, for example, the complex relationship between
food, nutrition, masculinity, femininity, identity and power relations was
absent. However, the Gender Impact Resource we compiled, contained
ample proof, for instance, of the differential access to food within house-
holds (Counihan and Kaplan, 1998; Messer, 1997; O’Doherty and Holm,
1999). Although ‘gender’ was mentioned in the Work Programme text on
ageing and disabilities, no specific problems were addressed. However,
articles retrieved from literature pointed to the medicalization of old age
and to the rise of a so-called ‘surveillance medicine’ requiring treatment
of risk factors. Both these processes affect older women and men differ-
ently (Clarke and Olesen, 1999). What was also missing, but cross-cutting
various research themes, was the notion of ‘doing gender’ affecting indi-
vidual health (Williams, 2000).
Using our GIA Protocol, we evaluated 303 projects of a particular call
for proposals (June 1999). Eighty-three projects received an indication, that
is: sex and/or gender aspects were relevant to the proposed research and
should be addressed. It appeared that 80 percent of the projects with an
indication in fact did not address these aspects. The projects that did
address sex and/or gender aspects did so only very tentatively. The inad-
equate manner in which sex differences were addressed and the overlook-
ing of gender aspects – found in various elements of the projects, such as
the composition of populations or consulted groups, methods for inter-
views and surveys, the design of technologies, the level of analysis and
the possibly gendered outcome/effects (in particular of policies) – did not
come as a big surprise. The Work Programme at the time did not explic-
itly address the possible relevance of sex and gender aspects, and thus few
research projects took due account of these. Nevertheless, carrying out the
GIA was a useful exercise. Our analysis provided ample evidence for
making clear and targeted recommendations. These were explicitly aimed
at improving the integration of the gender dimension in the next Frame-
work Programme (FP6).
RECOMMENDATIONS
Our general recommendations pertained to conducting gender-sensitive
research: how to address sex and/or gender aspects if relevant. Funding
should be made dependent on whether sex and gender aspects are
adequately addressed in research proposals. Two major recommendations
addressed FP6 research areas (‘Life Sciences, Genomics and Biotechnol-
ogy for Health’ and ‘Food Quality and Safety’) in which genomics are an
important feature. The existence of gene polymorphisms and the individ-
ualization of treatment and therapeutic substances it entails, require
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taking potential sex differences at the molecular level into account (Edi-
torial, 2001; Greaves, 1999; Greenberger, 2001; Wizemann and Pardue,
2001). Subsequent clinical studies should adhere to guidelines for the
inclusion of women in clinical studies. Another set of recommendations
was targeted at policy-oriented research and emergent needs. For
instance, we pointed to the need to address the unequal access of particu-
lar groups of women and ethnic minorities, the disabled and refugees to
health care services. We stressed the need to address the role of gender in
informal care, which is extremely relevant given the greying population of
Europe. Environmental and occupational health and ‘diseases without
diagnosis’ are conditions in which gender aspects are prominently
implied (Klinge and Bosch, 2001a).
DIALOGUE
Our GIA study was carried out in close collaboration between the
research team and the scientific staff of the Commission. In the early
stages, we became convinced that careful building of a dialogue between
the two parties involved, the gender experts and scientists (committed
scientific officers and policy-makers), was vital for the acceptance and, by
implication, for the future effect of our work. Thus, as gender experts, we
adopted an ‘educational style’ and invested in the development of a clear,
acceptable vocabulary for both parties. In this way it was possible to
overcome resistance to ‘value-loaded’ terms like gender bias or gender
sensitivity. Another strong feeling we encountered was the idea that
gender is not always relevant, with the inherent supposition that ‘we’
would think the opposite. We ‘tackled’ this by emphasizing the check on
gender relevance in our GIA Protocol. This left the option open that
gender in particular cases might not be relevant.
IMPLEMENTATION OF NEW GUIDELINES FOR EU
RESEARCH
The final reports of the seven GIA studies were issued and discussed at
the ‘Gender and Research’ Conference in November 2001 (European
Commission, 2001b, 2002a). One year later, in autumn 2002, FP6 texts
reflected the success of the GIA enterprise. All references to sex and
gender issues in the various FP6 texts have been brought together in the
publication Vademecum: Gender Mainstreaming in the 6th Framework
Programme – Reference Guide for Scientific Officers/Project Officers, issued
by DG RTD Women and Science Unit (Vademecum, 2003). The
implementation of our recommendations can be identified from various
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implementation documents such as the Guide for Proposers and the Guide
for Evaluators. The clear articulation of sex and gender differences is
conspicuous:
Because of the inconsistent and often confusing use of the terms sex and
gender, their use should be clarified: sex refers to differences attributed to
biological origins, gender refers to social influences that lead to differences.
Males and females differ not only in their basic biology but also in ways
they interact with and are treated by society. (Vademecum, 2003)
Researchers have to pay attention to gender aspects in research whenever
appropriate:
Scientific evidence of sex and gender differences in the incidence, preva-
lence and severity of a broad range of diseases, disorders and conditions has
shown that being female or male is an important variable that affects health
and illness through the life span. Genomic research in particular holds the
potential for uncovering the biological mechanisms of disease that underlie
many of those disorders that affect women and men differently.
Finally, attention to sex and gender aspects is made an evaluation
criterion:
Gender aspects in the research, concerning participation of women and
content of the proposal, will be included as part of the evaluation criteria for
selection for funding, by the evaluation panel.
In 2003, researchers writing proposals for research in Thematic Priority
1, ‘Life Sciences, Genomics and Biotechnology for Health’, were
confronted with specific questions in the application form, i.e. the B10.2
section headed ‘Gender Aspects in Research’. Some examples of those
questions are: ‘Does the project involve human subjects?’ ‘Does the project
use human cells/tissues/other specimens?’ ‘If human subjects are not
involved or human materials not used, does the research involve animal
subjects or animal tissues/cells/other specimen (as models of human
biology/physiology) in such a way that it is expected that it may have
implications for humans?’ The application form continues with: ‘a
positive answer to any of these questions implies that sex and/or gender
aspects should be taken into consideration in the research proposal’.
‘Taken into consideration’ means that researchers have to argue how sex
and gender aspects in relation to their research topic are taken into
account, based on existing literature.
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NEW WAYS OF DOING LIFE SCIENCES AND HEALTH
RESEARCH
In what follows, we give examples of FP6 research projects that have
taken the new guidelines for doing life sciences and health research into
account. We became acquainted with the projects because, since the
launch of FP6, we have become involved in a number of research projects
as gender experts, charged with the so-called Gender Action Plans of
Consortia.9
The first example is an application on depression in 2003, where a
particular Consortium (consisting of some 30 universities and institutes
working together) responded to the aforementioned B10.2 questions that
current knowledge pointed to the following differences (not exhaustive):
• Differences (m/f) in genetic and biological factors (neurotrans-
mitters, hormone levels);
• Differences in prevalence data between men and women (twice as
high in women);
• More co-morbidity in women;
• Differences in risk factors: social (gender) role, socioeconomic status,
living conditions, style of attribution, coping strategies.
Hypotheses have been put forward on the role of gender in available
prevalence data (f:m = 2:1) (Gijsbers van Wijk, 2002). The diagnosis of
depression is a descriptive one, based on recording a certain number of
symptoms over a certain period of time by the physician. Bearing in mind
the differences in the presentation of complaints between men and
women, it is not very difficult to see that women, who want to talk about
their symptoms when seeing their doctor, are more often diagnosed as
having a depression than men, who want a solution when seeing the
doctor. However, this could imply that depression is underdiagnosed in
men and that research designs based on current prevalence data could be
questioned. The relevant Consortium therefore proposed enrolling equal
numbers of women and men in a particular prospective study.
Other examples are two projects in which humans are involved as
objects of research, both in the Thematic Priority ‘Food Quality and
Safety’, which take due account of possible sex differences as well as
differences between men and women as effects of gender. Sex differences
have been documented in their susceptibility to diet-related diseases,
their acute and chronic response to nutrients and the distribution of
patterns of genetic coding or polymorphisms. Gender differences have
been detailed for risk perception, risk attitude, motivation with regard to
one’s own and the family nutrition, the processing of nutrition infor-
mation, and attendance to different elements of dietary advice, in which
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men and women encounter different barriers affecting behavioural
change.10 As a consequence, a particular work package investigating
consumer confidence in respect of risk analysis practices stipulates in
their quantitative survey that gender aspects will not only be taken into
account in the recruitment stage, but also in the research questions and in
the analysis of results. The research protocol will explicitly state a hypoth-
esis on gender issues.
The feasibility of the very new guidelines for preclinical research
concerning sex disaggregated data of animal experiments and notification
of the origin of cells and tissues is now being tested in the various funded
projects. The results of which will become available within the next two to
three years.
FEMINIST RESEARCH METHODOLOGIES IN LIFE SCIENCES
AND HEALTH RESEARCH: THEIR TRANSFORMATIVE
POTENTIAL
The formulation of recommendations for change of EU research practices
towards application of gender-sensitive methodologies made us rethink
strategies and strands in feminist theory. It is obvious that over the years
a distance has grown between women/gender and health researchers and
feminist theoreticians, labels used for explaining different directions of
research interest. This distance concerns issues of (the materiality of) the
body. Kuhlmann and Babitsch (2002) comprehensively addressed this
dissociation by discussing body concepts in recent feminist theories as
well as in women’s health research in their article ‘Bodies, Health, Gender:
Bridging Feminist Theories and Women’s Health’. They give a review of
statements on the body by feminist theoreticians like Butler, Haraway and
Grosz (among others) and compare those statements with work by gender
and health researchers like Doyal, Arber and West (and others).
Kuhlmann and Babitsch conclude that the selected feminist theoreticians
do make statements on the body, but that no connection can be made
between their statements and health problems or health issues because of
their focus on the deconstruction of the body as ‘natural’. (Gender)
scholars of various kinds (philosophers, science and technology scholars,
social scientists) are the consumers of these intriguing articles, books and
stories, but the ‘traditional’ health research community seems to neglect
them. Aspects highlighted in articles by gender and health researchers are
the relationship between socioeconomic circumstances and health and
phenomena like ‘doing gender is doing health’. Kuhlmann and Babitsch
draw attention to the fact that women/gender and health researchers
largely research issues outside the body, like the impact of socioeconomic
circumstances on health, and point out that serious attention to what is
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happening in the body is lacking. They go on to conclude that somehow
empirical research practices on the body/bodily processes are not
addressed by the two groups of researchers. The authors further contend
that gender and health researchers have tried to relate to theoretical
debates but that the opposite, theoreticians trying to relate to gender and
health issues, is lacking.11 The strong recommendation of Kuhlmann and
Babitsch is to ‘bring the material body back into feminist theory and to
further concepts that take the living and changing body into account’
(Kuhlmann and Babitsch, 2002: 433).
Reflecting on the work of Kuhlmann and Babitsch, it is clear that they are
addressing a long-standing debate between theory and practice and their
respective societal relevance. It is not our purpose here to go into this. A
second debate concerns the sex/gender question. Both groups of scholars
in fact primarily address gender: the feminist theoreticians because they
aim at deconstructing sex as well as the sex/gender opposition or division,
and the gender and health researchers because they focus on (social) issues
outside the body. We position ourselves somewhere in-between as feminist
gender studies scholars with an active interest in studying science as a
process and in changing actual research practices, especially in the life
sciences and health research. The focus in our GIA was on the practice of
life sciences and health research in terms of (methodological) content
(gender dimension) and context (women’s participation) of research. As
we did this in close dialogue with the scientific officers in Brussels, most of
whom are specialized in the field, it immediately became clear that
addressing the practice of life sciences and health research cannot be done
without giving due consideration to processes taking place in (material)
bodies. This meant that we realized from the start that we had to pay due
attention to possible sex differences (which was taken for granted by the
Brussels specialists) besides the role of gender (which was taken for
granted by us). To do so took some courage on our part and hours of
debate, because, as we have seen, paying attention to possible sex differ-
ences has not been ‘fashionable’ for a long time in feminist research for fear
of the essentializing practices of ‘traditional scientists’ who have been so
eager to define biological sex differences. Yet we invested in raising the
necessary focus on sex differences and on the effects of gender in research
on health and health care, and soon discovered that we were not alone in
this undertaking. Influential research agendas such as the ones of the
Office of Women’s Health Research at the National Institutes of Health
Research in the USA and of the Canadian Institutes of Health Research
have also stressed the importance of sex and gender and emphasized the
need for research questions related to both sex and gender in the analysis
and study of health and health problems. Agreeing with these agendas, we
stressed the usefulness of both terms and the conceptual distinction
between the two for life sciences and health research.
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Acknowledging the interaction between sex and gender, already
pointed to for a long time by feminist biologists like Lynda Birke and
Anne Fausto Sterling in their work, opens up possibilities for paying
attention to sex differences, effects of gender, as well as to the interaction
between the two. Or, put in other words: women and men are differen-
tially vulnerable to specific illnesses both through genetic causes (for
example, diseases linked to the sex chromosomes, frequency of mutations,
differing distributions in patterns of genetic coding or polymorphisms),
environmental exposures (for example, dangers in the workplace, bacter-
ial exposure, nutrition, violence, poverty, lifestyle) and combinations of
the two, as for example, epigenetic regulation (silent genes switched on by
the environment) (APA, 1996; NIH, 1999; Greaves, 1999). Interesting
research questions have also been raised by Elisabeth Wilson. She
wonders whether feminist stories on the anorectic body have taken note
of the biological function of the stomach, mouth and digestive system. She
asks: how many analyses of the ‘anxious body’ take neurological data into
account?
We now fully support the idea that a non-essentialist interest into what
is happening in bodies cannot be excluded from feminist research into the
body and health. We are of course aware that what is happening in bodies
is mediated by particular (gendered) technologies, but that does not
preclude due attention to the recorded phenomena, just because of insight
gained into these mediation processes. Consortia now applying for EU
funding in FP6 Thematic Priorities ‘Life Sciences, Genomics and Biotech-
nology for Health’ or ‘Food Quality and Safety’ have to address specific
questions on sex and gender in the application form (the B10 section). The
new guidelines for gender-sensitive EU research are even more important
for the following reason. As much biomedical research goes together with
a genomics component and thus will result in more attention to biological
factors as background, explanation and treatment of diseases, it is import-
ant to educate young researchers on how effects of gender can also be
involved in almost all health topics and should be taken into account. The
various training programmes of current research projects provide excel-
lent opportunities for this.
GENDER MAINSTREAMING OF EUROPEAN RESEARCH: A
GOOD PRACTICE
The implementation of the recommendations of the GIA studies in FP6 is
remarkable. We believe that we have created clarity by separating sex and
gender effects and that this clarity has contributed to convincing our
partners in DG Research of the relevance of sex and gender issues. As a
result, the relevant documents now contain the necessary boxes,
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explanations and examples. Moreover, the fact that issues of women’s
participation (WP) and of gender aspects of the research content (GD) will
be taken into account in several steps of the evaluation process (manage-
rial quality of research team, content of proposal) shows that in FP6 the
gender dimension is integrated as a criterion of quality. This reflects a true
characteristic of gender mainstreaming, i.e. not to develop measures for a
particular target group of women but to enhance the quality of a general
policy.
NOTES
1. We will not give full bibliographic details here. We refer to the comprehen-
sive overview given by Londa Schiebinger (1999) in her book Has Feminism
Changed Science? And to the research agendas like the NIH Agenda for
Research on Women’s Health for the 21st Century (NIH, 1999) and the Canadian
one: Sex, Gender and Women’s Health (Greaves, 1999), which list all relevant
publications.
2. The other reason for excluding women from clinical trials is because of a 100
percent protection of the unborn child.
3. In 1995, the Dutch Heart Foundation made women and heart disease a
priority theme. All kinds of educational activities were launched, among
which was a video, produced by Het Werktheater, for physicians to illus-
trate differences between men and women in presentation of complaints of
heart disease.
4. The original expression mainstreaming gender equality is sometimes abbre-
viated to mainstreaming gender or gender mainstreaming.
5. At the 1998 Women and Science conference, WISE adopted a motion that
stressed the attention to matters of research content parallel to women’s
participation.
6. The formula appeared for the first time in Vademecum (2003).
7. In this respect, an interesting intervention was made by Judith Lorber in
reaction to an example of a severe misunderstanding of the concepts sex and
gender between authors of a particular article in the British Medical Journal
and the authors of the Editorial highlighting that article (Lorber, 2001). She
provided a clear explanation of the difference between the two, in the same
terms as we do.
8. See GIA Protocol in Klinge and Bosch (2001b).
9. Recently the Commission has published a ‘Best Practice Compendium’ of
current Gender Action Plans of Consortia in several Thematic Priorities,
including 1 and 5 (October 2004).
10. These examples are taken from being involved as gender experts in several
large international projects (SAFEFOODS, NUGO, EUROPREVALL).
Gender experts in these projects are responsible for the implementation of
so-called Gender Action Plans (GAPs), which are monitored by the
Commission.
11. This article contains a much more detailed analysis than can be given here,
and we do not mean to reduce the argument of the authors to the selected
quotes.
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